跳至主要内容
临床试验/ITMCTR2023000054
ITMCTR2023000054招募中1 期

Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: a real-world pragmatic clinical trial

ational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taiwan0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 至 99(—)
性别
Female

入选标准

  • Patients aged more than 20 years, with a histologically confirmed diagnosis of breast cancer before the initiation of chemotherapy, are considered eligible for this study.

排除标准

  • Patients who will not be able to finish the chemotherapy and follow-up procedures, those who receive other medication, and those with an Eastern Cooperative Oncology Group (ECOG) score of 3–4 will be excluded from the study.

研究者

发起方
ational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taiwan

相似试验

Effectiveness of Chinese herbal medicine as a... | 临床试验